Bio-Techne Corp
TECHToday
+0.13%
5 Days
-0.30%
1 Month
+0.17%
6 Months
+42.43%
Year to Date
+23.31%
1 Year
+41.67%
Key Figures
• Clinical trial failures and regulatory delays for experimental therapies have pressured AstraZeneca’s share price. • Broad market rotation into cyclical sectors is driving capital outflows from defensive pharmaceutical stocks. • Emerging AI platforms for drug discovery are causing investors to reassess traditional pharmaceutical valuations.
• FDA approved Keytruda and Trodelvy for treating advanced triple-negative breast cancer. • FDA granted expanded indication for the pediatric pneumococcal vaccine Capvaxive. • Management increased 2026 revenue and earnings-per-share guidance projections.
• AbbVie agreed to acquire Apogee Therapeutics for approximately 10.9 billion dollars in cash. • The European Commission approved Skyrizi for pediatric patients with moderate-to-severe plaque psoriasis. • AbbVie declared a quarterly cash dividend of 1.73 dollars per share for shareholders.
Bio-Techne Corp's Score
Media Coverage
Analyst Rating
Bio-Techne Corp Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
Bio-Techne Corp Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.50% |
| BlackRock Institutional Trust Company, N.A. | 5.84% |
| Vanguard Portfolio Management, LLC | 4.14% |
| State Street Investment Management (US) | 3.71% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 60.06% |
| Investment Advisor/Hedge Fund | 37.12% |
| Hedge Fund | 9.13% |
| Research Firm | 2.58% |
Related Instruments
Popular Instruments
